๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) NCT06330064Phase 1, Phase 2120 sites๐Ÿ“ Los Angeles๐Ÿ“ Los Angeles๐Ÿ“ Whittier Daiichi Sankyo ยท Tests: Ifinatamab deruxtecan A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) NCT06601335Phase 32 sites๐Ÿ“ Wuhan๐Ÿ“ Chengdu Akeso ยท Tests: AK117 in combination with AK112, Placebo in combination with Pembrolizumab SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma NCT07254585Phase 21 site๐Ÿ“ Shanghai CSPC Megalith Biopharmaceutical Co.,Ltd. ยท Tests: SYS6010 injection, Enlonstobart injection, Pembrolizumab injection TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer NCT06868433Phase 12 sites๐Ÿ“ Atlanta๐Ÿ“ Atlanta Emory University ยท Tests: Autologous Tumor Membrane Vesicles Vaccine, Biospecimen Collection, Computed Tomography, Echocardiography, Magnetic Resโ€ฆ FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC NCT06788990Phase 2, Phase 3231 sites๐Ÿ“ Birmingham๐Ÿ“ Phoenix๐Ÿ“ La Jolla Bicara Therapeutics ยท Tests: Ficerafusp alfa, Pembrolizumab (KEYTRUDAยฎ), Placebo Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors NCT07584499Phase 11 site๐Ÿ“ Guangzhou Sun Yat-sen University ยท Tests: Becotatug Vedotin Study of TPEx Followed by a Maintenance With Avelumab and Cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma of the H&N NCT06640725Phase 21 site๐Ÿ“ Vandล“uvre-lรจs-Nancy Groupe Oncologie Radiotherapie Tete et Cou ยท Tests: Avelumab administration at 10mg/kg, Cetuximab (Erbitux) A Phase II Clinical Study to Evaluate HLX43 in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma NCT06857279Phase 22 sites๐Ÿ“ Jinan๐Ÿ“ Shanghai Shanghai Henlius Biotech ยท Tests: HLX43 DOSE 1, HLX43 DOSE 2, HLX43 DOSE 3, HLX43 DOSE 2 + HLX10, HLX43 DOSE 3 + HLX10 Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer NCT04415853Phase 31 site๐Ÿ“ Beijing Sunshine Lake Pharma Co., Ltd. ยท Tests: Lerotinib, Irinotecan/Tegafur A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors NCT06465069Phase 139 sites๐Ÿ“ Duarte๐Ÿ“ La Jolla๐Ÿ“ Los Angeles Eli Lilly and Company ยท Tests: LY4052031, Pembrolizumab Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC NCT05047094NA3 sites๐Ÿ“ Jerusalem๐Ÿ“ Ramat Gan๐Ÿ“ Tel Aviv Alpha Tau Medical LTD. ยท Tests: Diffusing Alpha Radiation Emitters Therapy (DaRT), Pembrolizumab Study of TI-0093 Injection With Recurrent/Metastatic HPV-16 Positive Solid Tumors NCT07081984Phase 11 site๐Ÿ“ Shanghai Therorna ยท Tests: therapeutic tumor vaccine A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression NCT06682793Phase 1, Phase 210 sites๐Ÿ“ Gilbert๐Ÿ“ La Jolla๐Ÿ“ Los Angeles A2 Biotherapeutics Inc. ยท Tests: A2B395, xT CDx with HLA-LOH assay KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer NCT07481058Phase 21 site๐Ÿ“ Beijing Beijing Konruns Pharmaceutical Co., Ltd. ยท Tests: KC1036, Toripalimab, Paclitaxel, Cisplatin, KC1036 Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic NCT07807345Phase 16 sites๐Ÿ“ Orlando๐Ÿ“ Boston๐Ÿ“ Oklahoma City Sutro Biopharma, Inc. ยท Tests: STRO-006, Pembrolizumab A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) NCT07408063Phase 21 site๐Ÿ“ Toronto University Health Network, Toronto ยท Tests: GSK5764227, Dostarlimab Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors NCT04119024Phase 13 sites๐Ÿ“ Duarte๐Ÿ“ Los Angeles๐Ÿ“ Stanford Anusha Kalbasi ยท Tests: Biopsy, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Fludarabine Phosphate A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy NCT06769113Phase 21 site๐Ÿ“ Jinan Shanghai Henlius Biotech ยท Tests: HLX43 Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy NCT05283226Phase 213 sites๐Ÿ“ Fullerton๐Ÿ“ Los Angeles๐Ÿ“ Boca Raton NATCO Pharma Ltd. ยท Tests: NRC-2694-A, Paclitaxel Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation NCT06662058NA1 site๐Ÿ“ Atlanta Emory University ยท Tests: Audiometric Test, Audiometric Test, Audiometric Test, Interview A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma NCT06769698Phase 238 sites๐Ÿ“ Los Angeles๐Ÿ“ Los Angeles๐Ÿ“ Orlando Regeneron Pharmaceuticals ยท Tests: FDC fianlimab+cemiplimab, Cemiplimab, Placebo Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in China NCT04857164Phase 21 site๐Ÿ“ Beijing Yuankai Shi ยท Tests: Pembrolizumab combined with Chemotherapy The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma NCT07290010Phase 21 site๐Ÿ“ Shijiazhuang Hebei Medical University Fourth Hospital ยท Tests: Iparomlimab and Tuvonralimab combined with chemotherapy Impact of Early Response to First-line Anti-PD-1 Monotherapy in Patients With Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma, Assessed by 18F-FDG PET/CT NCT07448727n/a1 site๐Ÿ“ Rome University of Rome Tor Vergata A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma NCT06753747Phase 1, Phase 21 site๐Ÿ“ Chengdu West China Hospital ยท Tests: Palbociclib, Afatinib(30mg), Afatinib(40mg), Afatinib(RP2D) A Study Investigating the Efficacy and Safety of the Combination of Iparomlimab and Tuvonralimab With or Without Chemotherapy in Second-line and Subsequent Treatments for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma NCT07546383NA1 site๐Ÿ“ Haikou The Second Affiliated Hospital of Hainan Medical University ยท Tests: Iparomlimab and tuvonralimab Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment NCT06589804Phase 3202 sites๐Ÿ“ Little Rock๐Ÿ“ Marysville๐Ÿ“ Palo Alto National Cancer Institute (NCI) ยท Tests: Biospecimen Collection, Cetuximab, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab A Study of BL-B16D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors NCT06469008Phase 11 site๐Ÿ“ Shanghai Sichuan Baili Pharmaceutical Co., Ltd. ยท Tests: BL-B16D1 Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study NCT07405086Phase 41 site๐Ÿ“ Portland OHSU Knight Cancer Institute ยท Tests: Biospecimen Collection, Immune Checkpoint Inhibitor Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors NCT04777994Phase 130 sites๐Ÿ“ Tucson๐Ÿ“ New Haven๐Ÿ“ Baltimore Calico Life Sciences LLC ยท Tests: ABBV-CLS-484, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Programmed Cell Deatโ€ฆ
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy